Literature DB >> 12087524

Burden of encephalitis-associated hospitalizations in the United States, 1988-1997.

Nino Khetsuriani1, Robert C Holman, Larry J Anderson.   

Abstract

Analysis of the National Hospital Discharge Survey data for 1988-1997 revealed a substantial disease burden associated with encephalitis in the United States: on average, there were nearly 19,000 hospitalizations (7.3 hospitalizations per 100,000 population), 230,000 hospital days, and 1400 deaths annually. For most encephalitis-associated hospitalizations (59.5%), the etiologic agent was unknown or not recorded; the most common etiologic categories among known causes were "viral" (38.2%) and "other infectious" (34.1%). The most common individual diagnoses with known agents were herpetic and toxoplasmic encephalitides (each associated with an annual average of 2100 hospitalizations). Human immunodeficiency virus infection was listed among discharge diagnoses for 15.6% of hospitalizations. Rates of encephalitis-associated hospitalization were highest for children <1 year old and persons > or =65 years old. The etiology of encephalitis was unknown for persons > or =65 years old significantly more often than it was for younger persons. The average cost of an encephalitis-associated hospitalization, as determined by the Healthcare Cost and Utilization Project for 1997, was $28,151, for an annual national cost of hospitalization of $650 million.

Entities:  

Mesh:

Year:  2002        PMID: 12087524     DOI: 10.1086/341301

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  58 in total

Review 1.  Neuro-intensive care of patients with acute CNS infections.

Authors:  J David Beckham; Kenneth L Tyler
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  Herpes Simplex Encephalitis: An Uncommon Presentation.

Authors:  Nidhi Kaeley; Sunil Bansal; Rohan Bhatia; Sohaib Ahmad
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 3.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Validation of laboratory screening criteria for herpes simplex virus testing of cerebrospinal fluid.

Authors:  Kimberly E Hanson; Barbara D Alexander; Christopher Woods; Cathy Petti; L Barth Reller
Journal:  J Clin Microbiol       Date:  2007-01-03       Impact factor: 5.948

Review 5.  Herpes Simplex Virus-1 Encephalitis in Adults: Pathophysiology, Diagnosis, and Management.

Authors:  Michael J Bradshaw; Arun Venkatesan
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

Review 6.  Disease modification in epilepsy: from animal models to clinical applications.

Authors:  Melissa L Barker-Haliski; Dan Friedman; Jacqueline A French; H Steve White
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

7.  Retrospective Review of Clinical Utility of Shotgun Metagenomic Sequencing Testing of Cerebrospinal Fluid from a U.S. Tertiary Care Medical Center.

Authors:  Kyle G Rodino; Michel Toledano; Andrew P Norgan; Bobbi S Pritt; Matthew J Binnicker; Joseph D Yao; Allen J Aksamit; Robin Patel
Journal:  J Clin Microbiol       Date:  2020-11-18       Impact factor: 5.948

8.  2-[4,5-Difluoro-2-(2-fluorobenzoylamino)-benzoylamino]benzoic acid, an antiviral compound with activity against acyclovir-resistant isolates of herpes simplex virus types 1 and 2.

Authors:  Mårten Strand; Koushikul Islam; Karin Edlund; Christopher T Oberg; Annika Allard; Tomas Bergström; Ya-Fang Mei; Mikael Elofsson; Göran Wadell
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

9.  Effect of combinations of antiviral drugs on herpes simplex encephalitis.

Authors:  Bryan M Gebhardt; Federico Focher; Richard Eberle; Andrzej Manikowski; George E Wright
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

10.  Etiology of encephalitis in Australia, 1990-2007.

Authors:  Clare Huppatz; David N Durrheim; Christopher Levi; Craig Dalton; David Williams; Mark S Clements; Paul M Kelly
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.